GHRP-2 Acetate vs Hexarelin — Peptide Comparison

GHRP-2 Acetate vs Hexarelin — Peptide Comparison GHRP-2 Acetate vs Hexarelin: both boost GH, but Hexarelin spikes cortisol harder and desensitizes faster. Real Peptides explains potency, side effects, … Hexarelin is the most potent growth hormone secretagogue available. Until it stops working. Research published in the Journal of Clinical Endocrinology & Metabolism found that Hexarelin-induced GH secretion drops by as much as 50% after just 14 consecutive days of administration, a desensitization rate significantly faster than GHRP-2 Acetate. That difference matters when you're designing multi-week protocols. We've supplied both peptides to hundreds of research institutions. The gap between doing it right and doing it wrong comes down to understanding mechanism, potency curves, and when rapid desensitization turns a promising compound into an expensive control variable. What is the difference between GHRP-2 Acetate and Hexarelin? GHRP-2 Acetate and Hexarelin are both growth hormone-releasing peptides (GHRPs) that bind to ghrelin receptors, but Hexarelin produces stronger GH secretion (up to 2x higher peak levels in some models) while also elevating cortisol and prolactin more aggressively. GHRP-2 Acetate exhibits milder receptor desensitization, making it better suited for sustained multi-week studies, whereas Hexarelin's potency peaks early but tapers faster. Yes, GHRP-2 Acetate vs Hexarelin is a meaningful distinction. Not just a brand choice. The same dose of Hexarelin can produce GH pulses 1.5–2x higher than GHRP-2 Acetate during the first week of administration, but that advantage erodes rapidly as ghrelin receptor sensitivity declines. Meanwhile, GHRP-2 Acetate maintains more consistent secretion across weeks 2–6, though at lower peak amplitude. The choice depends on whether your research prioritizes acute maximal GH release or sustained elevation over time. This piece covers receptor pharmacology, dosing kinetics, side effect profiles, and protocol design strategies for both peptides. Both GHRP-2 Acetate and Hexarelin function as ghrelin receptor agonists (also called growth hormone secretagogue receptors, or GHS-R1a), binding to sites in the pituitary and hypothalamus to trigger endogenous growth hormone release. The mechanism is not exogenous GH administration. These peptides signal the pituitary to secrete its own stores, producing pulsatile GH elevation that more closely mimics natural physiological rhythms than continuous GH infusion. Hexarelin binds with higher affinity to GHS-R1a than GHRP-2 Acetate, producing stronger receptor activation per molecule. In comparative studies, Hexarelin at 100mcg subcutaneous injection produced peak GH levels 1.8–2.1x higher than GHRP-2 Acetate at the same dose within 30 minutes post-administration. This potency difference stems from Hexarelin's modified amino acid sequence. It contains a methylated tryptophan residue that increases receptor selectivity and binding duration. However, stronger binding brings a trade-off: receptor desensitization. Continuous or daily Hexarelin administration downregulates GHS-R1a expression in the pituitary within 10–14 days, reducing subsequent GH response even as dosing continues. GHRP-2 Acetate desensitizes more slowly, with studies showing sustained GH secretion across 4–6 weeks of daily dosing before response attenuation becomes statistically significant. Research groups designing longitudinal growth hormone studies must account for this kinetic difference when selecting between GHRP-2 Acetate vs Hexarelin as the primary agonist. Both peptides also stimulate ACTH (adrenocorticotropic hormone) and cortisol secretion, though Hexarelin produces significantly higher cortisol spikes. Approximately 3x the cortisol elevation seen with GHRP-2 Acetate at equivalent GH-inducing doses. Prolactin elevation is similarly more pronounced with Hexarelin. These secondary hormonal effects can confound metabolic studies unless controlled for or monitored independently. Potency is not a fixed value. It changes with time, dose frequency, and receptor saturation. Hexarelin's initial advantage in peak GH secretion erodes within two weeks of daily administration, a phenomenon documented in multiple phase I clinical trials. One study in healthy male subjects found that Hexarelin 2mcg/kg daily produced GH levels of 18.4 ng/mL on day 1, but only 9.7 ng/mL on day 14. A 47% reduction despite unchanged dosing. GHRP-2 Acetate shows a flatter desensitization curve. Research using 1mcg/kg daily dosing over 28 days found GH response declined by approximately 18–22% by week four. Significant, but far less steep than Hexarelin's trajectory. For studies requiring consistent GH elevation beyond two weeks, GHRP-2 Acetate offers more predictable kinetics. Dosing protocols differ accordingly. Hexarelin is typically administered at 100–200mcg per dose, 1–2 times daily, with cycling (5 days on, 2 days off, or 2 weeks on, 1 week off) to mitigate desensitization. GHRP-2 Acetate is dosed at 100–300mcg per administration, 2–3 times daily, with continuous protocols viable for 4–6 weeks before washout becomes necessary. Timing relative to meals matters. Both peptides produce stronger GH pulses when administered on an empty stomach, as elevated glucose and insulin blunt ghrelin receptor signaling. The half-life of both peptides is short. Approximately 30–60 minutes in plasma. Meaning GH elevation is transient. Peak GH occurs 20–40 minutes post-injection and returns to baseline within 2–3 hours. Multi-dose daily protocols are designed to create repeated pulses rather than sustained elevation, which more closely mirrors endogenous GH secretion patterns and reduces negative feedback suppression. We've seen research groups make the mistake of assuming higher potency always means better outcomes. One lab switched from GHRP-2 Acetate to Hexarelin mid-study to 'boost GH response' and saw their week-three data become statistically meaningless as receptor desensitization invalidated comparisons to baseline. Protocol continuity matters. Switching peptides mid-study introduces a pharmacokinetic confound that can't be corrected retroactively. The most significant difference between GHRP-2 Acetate vs Hexarelin is not GH potency. It's the secondary hormonal cascade each peptide triggers. Hexarelin elevates cortisol and prolactin far more aggressively than GHRP-2 Acetate, which can confound metabolic, immune, or stress-response studies if not accounted for. In a head-to-head comparison published in the European Journal of Endocrinology, Hexarelin 2mcg/kg produced cortisol increases of 12.3 mcg/dL above baseline, whereas GHRP-2 Acetate at the same dose raised cortisol by only 4.1 mcg/dL. Prolactin showed a similar pattern: Hexarelin elevated prolactin by 18.7 ng/mL versus 6.2 ng/mL for GHRP-2 Acetate. These differences persist across dose ranges and are intrinsic to the peptides' receptor binding profiles, not artifacts of dosing errors. Cortisol elevation is dose-dependent and transient, peaking 30–60 minutes post-injection and returning to baseline within 3–4 hours. However, repeated daily spikes can alter stress axis signaling over multi-week protocols. Research groups studying GH effects on body composition, insulin sensitivity, or immune function must distinguish between GH-mediated changes and cortisol-mediated confounds. Particularly when using Hexarelin. GHRP-2 Acetate also raises cortisol and prolactin, but the magnitude is lower and the impact on downstream endpoints is less likely to introduce bias. For studies where cortisol is a primary or secondary outcome variable, GHRP-2 Acetate is the cleaner tool. Hexarelin's potency advantage comes at the cost of a noisier hormonal profile. Both peptides stimulate hunger through ghrelin receptor activation, though subjective reports suggest Hexarelin produces slightly stronger appetite stimulation. This effect is leveraged intentionally in cachexia and wasting syndrome research but can be a confound in metabolic studies where caloric intake is meant to be controlled. Neither peptide has been associated with significant adverse events in short-term clinical trials at standard research doses, but long-term safety data beyond 12 weeks is limited. Injection site reactions (redness, mild irritation) occur in approximately 5–10% of administrations and resolve without intervention. Our peptides are supplied as lyophilised powder and must be reconstituted with bacteriostatic water before subcutaneous injection. Improper reconstitution is the most common source of protocol errors. The table below summarizes the key pharmacological, dosing, and application differences between GHRP-2 Acetate and Hexarelin based on peer-reviewed research and observed kinetics in controlled studies. GH Peak Potency (100mcg dose) Moderate. Produces 8–12 ng/mL peak GH in most models High. Produces 15–22 ng/mL peak GH in first-week administration Hexarelin delivers stronger acute GH pulses initially Receptor Desensitization Timeline Slow. GH response declines ~18–22% by week 4 of daily dosing Rapid. GH response declines ~40–50% by week 2 of daily dosing GHRP-2 Acetate maintains consistency longer Cortisol Elevation (per dose) Mild. Approximately 4 mcg/dL above baseline High. Approximately 12 mcg/dL above baseline Hexarelin produces 3x higher cortisol spikes Prolactin Elevation (per dose) Low. Approximately 6 ng/mL above baseline Moderate. Approximately 18 ng/mL above baseline GHRP-2 Acetate has lower prolactin impact Typical Dosing Range 100–300mcg per dose, 2–3x daily 100–200mcg per dose, 1–2x daily with cycling Hexarelin requires cycling; GHRP-2 can run continuously Optimal Study Duration 4–6 weeks continuous before washout needed 2 weeks on, 1 week off cycling to preserve response Protocol design depends on study length Best Use Case Sustained multi-week GH studies with minimal cortisol confounds Short-duration studies requiring maximal acute GH secretion Choose based on endpoint timeline and hormonal tolerance Hexarelin produces 1.5–2x higher peak GH levels than GHRP-2 Acetate during the first week, but receptor desensitization reduces this advantage by 40–50% within two weeks of daily dosing. GHRP-2 Acetate shows slower desensitization, maintaining GH response across 4–6 weeks of continuous daily administration with only 18–22% decline in secretion. Hexarelin elevates cortisol approximately 3x higher than GHRP-2 Acetate at equivalent GH-stimulating doses, which can confound metabolic and stress-response studies. Both peptides have plasma half-lives of 30–60 minutes and produce transient GH pulses peaking 20–40 minutes post-injection. They do not create sustained GH elevation. Cycling protocols (e.g., 5 days on, 2 days off) are essential for Hexarelin to preserve receptor sensitivity, whereas GHRP-2 Acetate can be dosed continuously for 4–6 weeks before washout. Neither peptide is exogenous GH. Both are ghrelin receptor agonists that signal the pituitary to release endogenous growth hormone stores. Use Hexarelin. Its higher receptor affinity produces stronger acute GH pulses within the first 10–14 days before desensitization becomes a limiting factor. Dose at 100–200mcg subcutaneously 1–2 times daily on an empty stomach. Monitor cortisol and prolactin as secondary endpoints to distinguish GH-mediated effects from confounding hormonal changes. If the study extends beyond two weeks, either cycle Hexarelin (2 weeks on, 1 week off) or switch to GHRP-2 Acetate to maintain consistent GH response. Choose GHRP-2 Acetate. Its slower desensitization profile allows continuous daily dosing across 4–6 weeks without the steep response drop-off seen with Hexarelin. Dose at 100–300mcg 2–3 times daily, spaced at least 4 hours apart. Administer on an empty stomach to maximize ghrelin receptor activation. By week six, expect GH response to decline by approximately 20% from baseline. Still far more stable than Hexarelin's 50% decline by week two. GHRP-2 Acetate is the cleaner option. Its cortisol spike is roughly one-third that of Hexarelin at equivalent GH-stimulating doses, reducing the likelihood that cortisol-mediated metabolic changes confound your GH-related endpoints. If your research examines insulin sensitivity, body composition, or immune markers. All of which cortisol influences independently. The lower cortisol burden of GHRP-2 Acetate improves internal validity. Hexarelin's cortisol elevation isn't a flaw, but it introduces a variable that must be measured and controlled. No. Increasing the dose accelerates receptor desensitization further and risks overshooting cortisol and prolactin thresholds without restoring GH response. Instead, implement a washout period. Discontinue the peptide for 7–14 days to allow GHS-R1a receptor upregulation, then resume at the original dose. Alternatively, if study design allows, switch peptides: if using Hexarelin, transition to GHRP-2 Acetate for the remainder of the protocol. Dose escalation mid-study to compensate for desensitization is a common error that compromises data integrity. Here's the honest answer: Hexarelin is not 'better' than GHRP-2 Acetate. It's sharper and shorter. If your study timeline is under two weeks and you need maximum GH secretion, Hexarelin is the right tool. If your protocol runs four weeks or longer and requires stable, reproducible GH pulses without steep desensitization, GHRP-2 Acetate is the only rational choice. The mistake is treating them as interchangeable. Most research groups that abandon Hexarelin mid-study do so because they didn't account for receptor desensitization timelines. By week three, their GH data no longer correlates with dose or timing, and the study loses statistical power. GHRP-2 Acetate doesn't give you the dramatic early spike, but it gives you consistency. Which matters far more when you're analyzing week-four endpoints or running longitudinal metabolic studies. The cortisol difference is not trivial. Hexarelin's 3x higher cortisol elevation can shift insulin sensitivity, alter body composition metrics, and confound immune markers independent of GH. If cortisol is measured only as a safety variable and not a controlled endpoint, you risk attributing GH-mediated outcomes to changes that cortisol actually drove. GHRP-2 Acetate doesn't eliminate cortisol elevation, but it reduces it to a level where confounding is far less likely. Both peptides require precise reconstitution with bacteriostatic water and refrigerated storage at 2–8°C post-reconstitution. A single temperature excursion above 8°C can denature the peptide structure irreversibly, turning an effective compound into an expensive saline injection. We've supplied both GHRP-2 and Hexarelin to labs that demand exact amino acid sequencing and third-party purity verification. Quality at the synthesis stage determines whether your endpoints are valid or artifacts of degraded material. Understanding GHRP-2 Acetate vs Hexarelin isn't about choosing the 'strongest' peptide. It's about matching pharmacokinetics to study design. Potency without stability is noise. Stability without potency may miss acute-phase endpoints. The right peptide depends on whether your research prioritizes peak amplitude or sustained elevation. And whether your protocol can tolerate Hexarelin's cortisol and desensitization trade-offs or requires GHRP-2 Acetate's steadier kinetic profile. Hexarelin produces 1.5–2x higher peak GH levels than GHRP-2 Acetate during the first week of administration due to stronger ghrelin receptor binding affinity. However, this potency advantage erodes rapidly — Hexarelin-induced GH secretion declines by 40–50% within two weeks of daily dosing due to receptor desensitization, whereas GHRP-2 Acetate maintains more consistent GH response across 4–6 weeks with only 18–22% decline. The difference is not just magnitude but duration of effect. Continuous daily Hexarelin administration beyond two weeks results in significant receptor desensitization, reducing GH response by approximately 50% even if dosing remains constant. To preserve effectiveness, Hexarelin must be cycled — typically 5 days on and 2 days off, or 2 weeks on followed by 1 week off. If your study requires uninterrupted daily dosing for more than two weeks, GHRP-2 Acetate is a more appropriate choice as it exhibits slower desensitization kinetics. Both peptides are comparably priced per milligram, but total study cost depends on dosing frequency and cycling requirements. GHRP-2 Acetate can be dosed continuously at 100–300mcg 2–3 times daily for four weeks without cycling, whereas Hexarelin requires either dose cycling or higher per-administration amounts to compensate for desensitization. A four-week protocol using GHRP-2 Acetate typically consumes 16.8–25.2mg total, while Hexarelin with cycling consumes 11.2–16.8mg but may require dose escalation to maintain response — making effective cost similar despite different kinetics. Hexarelin elevates cortisol approximately 3x higher than GHRP-2 Acetate at equivalent GH-stimulating doses, which can confound metabolic endpoints. Cortisol independently influences insulin sensitivity, promotes gluconeogenesis, and alters body composition through catabolic signaling — effects that may be incorrectly attributed to GH if cortisol is not measured as a controlled variable. In studies examining glucose metabolism, fat oxidation, or lean mass changes, Hexarelin’s cortisol spike introduces a confounding variable that requires either statistical adjustment or selection of GHRP-2 Acetate as the cleaner tool. GHRP-2 Acetate elevates cortisol and prolactin moderately, whereas Ipamorelin produces minimal cortisol or prolactin elevation and is considered the most selective GH secretagogue available. Ipamorelin’s selectivity comes at the cost of lower peak GH secretion — it produces approximately 60–70% the GH pulse amplitude of GHRP-2 Acetate at equivalent doses. For studies prioritizing hormonal selectivity and minimal side effects, Ipamorelin is the preferred option; for studies requiring stronger GH pulses with acceptable cortisol elevation, GHRP-2 Acetate is more appropriate. GHRP-2 Acetate is better suited for long-term studies lasting four weeks or more because it exhibits slower receptor desensitization. Continuous daily GHRP-2 Acetate dosing maintains GH response across 4–6 weeks with only 18–22% decline,